Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > On GLP-1 agonists US Senate passes anti-patent thicket bill

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Sep 03, 2024 10:00am

93 Views

Post# 36206015

RE:RE:RE:RE:RE:RE:On GLP-1 agonists US Senate passes anti-patent thicket bill

Should read: " ... Pfizer's right to its trastuzumab-deruxtecan ADC product will now have to be under license from Daiichi-Sanyo ..." with royalties having to be paid from Pfizer to Daiichi Sanyo on any negotiated licensing agreement.

<< Previous

Bullboard Posts

Next >>

Soma Gold poised to extend profitable track record